euro-toxicology-2016_scientifictracks-abstracts

73 / 89

Volume 6, Issue 6(Suppl) J Clin Toxicol 2016
ISSN: 2161-0495, JCT an open access journal
Page 119
Notes:
Euro Toxicology 2016
October 24-26, 2016
conferenceseries.com
Toxicology & Applied Pharmacology
October 24-26, 2016 Rome, Italy
7th Euro-Global Summit on
Individualised clinical toxicology: Physiological intermolecular modulation spectroscopy (PIMS),
a technology to forsee drugs efficacy prior to administration
Pierre Eftekhari
Inoviem Scientific, France
Toxicology today is in need of new insight. In air of individualised medicine the relation between desired clinical effect and
toxic or side-effects should be considered simultaneously. Genomics, proteomics, metabolomics and omics in general,
although extremely valuable, are globally lacking clinical relevance. Therefore, there is a need for new methodologies and new
tools enabling us to make a bridge between predicted omics-based drug toxicity and clinics. Here, I shall present Physiological
Intermolecular Modulation Spectroscopy (PIMS) a cutting edge techology meant to stratify the patients as responders or
non-responders in regard to a pharmacological active agent. PIMS provides individual fingerprints based on drug-induced
macromolecular modulation directly on human tissue extracts. I will explain the scientific background of PIMS and present
the results from two different clinical studies (transversal and longitudinal), using peripheral blood mononuclear cells (PBMC)
isolated from patients with ulcerative colitis and Crohn’s disease for the prediction of infliximab effect.
Biography
Pierre Eftekhari has completed his PhD from Strasbourg University. He has more than 19 years of experience in Drug Development and is the President of Inoviem
Scientific, a company dedicated to cutting edge solutions in drug development. He has published more than 30 papers in reputed journals and filed several patents.
Pierre Eftekhari, J Clin Toxicol 2016, 6:6(Suppl)